加载中
NASDAQHealthcareBiotechnology
最新数据
US$12.97
−US$0.77 · -5.60%
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
常规交易时段
US$12.97
−US$0.77 · -5.60%
盘中时间采用ET。市场数据可能有所延迟。
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
日内区间
当前US$12.97
52周区间
当前US$12.97
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
47
合理估值
情绪
43
多空交织
风险
80
高风险
动量
26
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
日内区间
当前US$12.97
52周区间
当前US$12.97
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6722.1万 USD | 1.38亿 USD | 1.58亿 USD | 2.06亿 USD | 1235.9万 USD |
| 销货成本 | 302.5万 USD | — | — | — | — |
| 毛利 | 6419.6万 USD | 1.38亿 USD | 1.58亿 USD | 2.06亿 USD | 1235.9万 USD |
| 研究与开发 | 1.12亿 USD | 1.95亿 USD | 1.92亿 USD | 1.48亿 USD | 1.74亿 USD |
| 销售、一般及管理费用 | 4607.9万 USD | 5282.3万 USD | 5287.1万 USD | 4607.1万 USD | 4145.1万 USD |
| 营业费用 | 1.39亿 USD | 2.34亿 USD | 2.36亿 USD | 1.94亿 USD | 2.15亿 USD |
| 利息收入 | 1009.5万 USD | 1519.5万 USD | 1735.9万 USD | 258.1万 USD | 75.3万 USD |
| 利息支出 | — | — | 76.7万 USD | 300.1万 USD | 267.4万 USD |
| 折旧和摊销 | 302.5万 USD | 354.4万 USD | 295.7万 USD | 152.7万 USD | 119.3万 USD |
| 营业利润 | −7495.5万 USD | −9566.9万 USD | −7820.5万 USD | 1217.7万 USD | −2.03亿 USD |
| 净利润 | −6578.3万 USD | −8094.1万 USD | −2972.5万 USD | 934.9万 USD | −2.04亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
ARK Genomic Revolution ETFARKG3628.35万1.77%15.57亿 USD0.75%US$49.715-3.09%
Vanguard Morningstar Total Stock Market ETFVTI1176.6万0.00%2.3万亿 USD0.03%US$382.01+0.02%
iShares Russell 2000 ETFIWM969.42万0.01%787.4亿 USD0.19%US$278.75-0.07%
Vanguard Extended Market ETFVXF460.73万0.00%954亿 USD0.05%US$234.44-0.24%
iShares Biotechnology ETFIBB287.26万0.03%108.2亿 USD0.44%US$205.36-0.55%
Vanguard Russell 2000 ETFVTWO227.5万0.01%180亿 USD0.06%US$112.6-0.05%
Schwab U.S. Small-Cap ETFSCHA176.42万0.01%218.24亿 USD0.03%US$32.785-0.02%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS141.11万0.35%3.99亿 USD0.60%US$106.82-0.39%ARK Genomic Revolution ETFARKGVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAInvesco Dorsey Wright SmallCap Momentum ETFDWASAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
